Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX)‘s stock had its “sector perform” rating reiterated by equities research analysts at Royal Bank Of Canada in a report released on Monday, StockTargetPrices.com reports. They currently have a C$39.00 price objective on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price objective points to a potential upside of 69.86% from the stock’s previous close.
Several other equities analysts have also recently commented on VRX. Scotiabank lowered their target price on shares of Valeant Pharmaceuticals Intl from C$34.00 to C$32.00 and set a “sector perform” rating on the stock in a research note on Tuesday, November 1st. TD Securities lowered their target price on shares of Valeant Pharmaceuticals Intl from C$38.50 to C$18.00 and set a “hold” rating on the stock in a research note on Thursday, November 10th.
Shares of Valeant Pharmaceuticals Intl (TSE:VRX) traded up 0.65% during trading on Monday, hitting $23.11. 308,590 shares of the company traded hands. The firm has a 50 day moving average price of $26.49 and a 200-day moving average price of $31.56. The stock’s market cap is $8.03 billion. Valeant Pharmaceuticals Intl has a one year low of $18.41 and a one year high of $165.77.
About Valeant Pharmaceuticals Intl